<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544362</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564075</org_study_id>
    <secondary_id>FFCD-0505</secondary_id>
    <secondary_id>EU-20756</secondary_id>
    <secondary_id>EUDRACT-2006-004770-27</secondary_id>
    <secondary_id>MERCK-FFCD-0505</secondary_id>
    <nct_id>NCT00544362</nct_id>
  </id_info>
  <brief_title>Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Neoadjuvant Treatment for Operable Esophageal Cancer With 5-fluorouracil, Cisplatin, and Cetuximab and Concurrent Radiotherapy: Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
      Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
      kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy
      x-rays to kill tumor cells. Giving fluorouracil and cisplatin together with cetuximab and
      radiation therapy may kill more tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of fluorouracil and
      cisplatin when given together with cetuximab and radiation therapy in treating patients with
      esophageal cancer that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the maximum tolerated dose of fluorouracil and cisplatin when administered
           with cetuximab concurrently with esophageal radiotherapy. (Phase I)

        -  To determine the complete histological response rate (after surgical resection). (Phase
           II)

      Secondary

        -  To determine progression-free survival and overall survival. (Phase II)

        -  To determine the rate of resection with negative margins (R0). (Phase II)

        -  To determine the overall tolerance to neoadjuvant therapy. (Phase II)

        -  To determine the postoperative morbidity and mortality. (Phase II)

      OUTLINE: This is a multicenter study. This is a dose-escalation study of cisplatin and
      fluorouracil.

      Patients receive cetuximab IV over 2 hours on day -7, then IV over 1 hour on days 1, 8, 15,
      22, and 29. Patients also receive cisplatin IV over 1 hour on day 1 or 2 and fluorouracil IV
      continuously on days 1-4, 8-11, 15-18, 22-25, and 29-32. Patients undergo radiotherapy 5 days
      a week for 5 weeks, beginning on day 1 of chemotherapy. Treatment continues in the absence of
      disease progression or unacceptable toxicity.

      Patients undergo surgery within 6-8 weeks after completion of chemoradiotherapy.

      After completion of study therapy, patients are followed at 1 month, every 4 months for 2
      years, and then every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete histologic response</measure>
    <time_frame>After Surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerance to neoadjuvant therapy</measure>
    <time_frame>From Inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free and overall survival</measure>
    <time_frame>From inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From Inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically confirmed epidermoid or glandular carcinoma of the thoracic esophagus

               -  Invasive disease

               -  Only Siewert type I gastroesophageal carcinoma allowed

          -  Resectable disease

               -  T1N+, T2N0, T2N+, T3N0, or T3N+ (stage II or III)

               -  No visceral metastases or mediastinal extensions compromising resectability

        Exclusion criteria:

          -  Inoperable disease

          -  Invasion of the tracheo-bronchial tree

          -  Recurring esophageal paralysis

          -  Esopho-tracheal fistula

          -  Cervical esophageal carcinoma (&lt; 19 cm above the dental arches)

          -  Multifocal esophageal carcinoma

          -  Superficial esophageal carcinoma (T1N0)

          -  Esophageal carcinoma in the lymph nodes that cannot be included in the radiotherapy
             field or cannot be completely surgically resected

          -  Proven metastatic disease

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  WHO performance status 0-1

          -  Weight loss &lt; 15%

          -  Absolute neutrophil count ≥ 1,500/mm3

          -  Platelet count ≥ 100,000/mm3

          -  Creatinine ≤ 1.25 times upper limit of normal

          -  PTT ≥ 80%

          -  Albumin ≥ 35 g/L

          -  FEV1 &gt; 1 L

          -  Not pregnant or nursing

          -  Fertile patients of must use effective contraception

        Exclusion criteria:

          -  Known liver cirrhosis

          -  Renal insufficiency

          -  Respiratory insufficiency (i.e., severe dyspnea at rest or oxygen dependence)

          -  Progressive coronary insufficiency

          -  Myocardial infarction in the past 6 months

          -  Legally incapacitated

          -  Impossible to receive study therapy due to geographical, social, or psychological
             reasons

          -  Noncompliant within constraints of the study

          -  Hematologic malignancy or other cancer except carcinoma in situ of the uterine cervix,
             treated nonmelanoma skin cancer, or intramucous disease treated within the past 3
             years

        PRIOR CONCURRENT THERAPY:

        Exclusion criteria:

          -  Prior anticancer chemotherapy or radiotherapy

          -  Treatment with endoprosthesis

          -  Surgery (esophagectomy) planned without thoracotomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Schneider</last_name>
    <role>Study Chair</role>
    <affiliation>Federation Francophone de Cancerologie Digestive</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Clermont Ferrand, Hotel Dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federation Francophone de Cancerologie Digestive</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Universitaire Hop Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>stage IIIC esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

